| DIRECT COMPETITOR COMPARISON | |
| QGEN | LIFE | Pvt1 | SIAL | Industry | | Market Cap: | 5.04B | 9.03B | N/A | 6.44B | 98.96M | | Employees: | 3,300 | 9,700 | N/A | 7,800 | 65 | | Qtrly Rev Growth (yoy): | 12.50% | 121.40% | N/A | -1.30% | 19.70% | | Revenue (ttm): | 957.93M | 2.95B | N/A | 2.08B | 14.01M | | Gross Margin (ttm): | 66.58% | 64.07% | N/A | 51.23% | 65.68% | | EBITDA (ttm): | 302.51M | 818.22M | N/A | 578.40M | -12.30M | | Oper Margins (ttm): | 19.73% | 15.72% | N/A | 23.34% | -137.11% | | Net Income (ttm): | 117.99M | 7.87M | N/A | 338.40M | N/A | | EPS (ttm): | 0.577 | 0.049 | N/A | 2.731 | -0.31 | | P/E (ttm): | 37.82 | 1033.47 | N/A | 19.36 | 17.26 | | PEG (5 yr expected): | 1.28 | 1.5 | N/A | 2.12 | 1.28 | | P/S (ttm): | 5.31 | 3.04 | N/A | 3.09 | 9.45 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LIFE | | Living the Good Second Life
Fri, Dec 4 -
FOX Business Now | | • | SIAL | | Sigma-Aldrichâs rat breakthrough hailed as top innovation
Thu, Dec 3 -
at bizjournals.com | | • | LIFE | | Behind the Business: 3 Questions for Vical
Thu, Dec 3 -
at Motley Fool | | • | SIAL | | Sigma-Aldrich's Targeted Knockout Rat Ranks in Top Five of The Scientist Magazine's Top 10 Innovations of 2009
Thu, Dec 3 -
PR Newswire | | • | SIAL | | Sell Cu, Buy Au, Ag, K2CO3
Wed, Dec 2 -
Wall Street Transcript | | • | LIFE | | Luminex Posts Loss
Mon, Nov 30 -
Zacks.com | | • | LIFE | | InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
Wed, Nov 25 -
GlobeNewswire | | • | SIAL | | Sigma-Aldrich to Present at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009
Tue, Nov 24 -
PR Newswire | | • | LIFE | | Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Fri, Nov 20 -
Wall Street Transcript | | • | LIFE | | Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
Thu, Nov 19 -
GlobeNewswire | | • | SIAL | | Sigma-Aldrich Launches 'What's Your Favorite Gene?' Application On Facebook(R) Platform
Wed, Nov 18 -
PR Newswire | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
0.18 (0.82%) 
Competitors
